



MEDIA RELEASE

International Liver Specialist Professor Ed Gane to Join Invictus BioPharma Scientific Advisory Board

Melbourne Australia 21 March 2019 – Invictus BioPharma Limited, the Company commercialising an innovative non-invasive direct drug and vitamin delivery platform, today announced the appointment of internationally respected hepatologist Professor Ed Gane as a member of its Scientific Advisory Board.

Professor Gane's knowledge and experience will help guide the development of the formal protocols for the Company's pending Phase II clinical study for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Commenting on his appointment, Prof Gane said, "There is a significant unmet need for an effective and well-tolerated treatment for NAFLD and NASH. Invictus BioPharma's non-invasive and direct delivery platforms have the potential to be developed into effective drugs for these diseases and I am delighted to take this opportunity to participate in the Company's clinical development programs."

Dr Gane is Professor of Medicine at the University of Auckland, New Zealand, Hepatologist and Deputy Director of the New Zealand Liver Unit at the Auckland City Hospital.

He trained at the Institute of Liver Studies, King's College School of Medicine, London, where he completed his doctorate on the pathogenesis of hepatitis C-related liver injury.

Dr Gane is an investigator for many international clinical trials with particular interest in early phase development of therapies for non-alcoholic fatty liver disease and new direct acting antiviral therapies against chronic hepatitis C and hepatitis B.



He has published more than 300 peer-reviewed papers in journals such as The Lancet and The New England Journal of Medicine. Dr Gane was made a Member of the Order of New Zealand in 2011. He is a Fellow of the Royal Society of New Zealand.

Tocotrienols address NAFLD/NASH by inhibiting the production of inflammatory cytokines resulting from oxidative stress which then activate fat-storing cells in the liver which in turn produces collagen and causes scarring (fibrosis). Invictus BioPharma's NAFLD/NASH drug candidates have the potential to inhibit fibrosis in the liver and are based on delivery platforms that allow direct delivery of the drug in a non-invasive way which improves the amount of the drug circulating in the blood (bioavailability).

For more information please contact:

Dr Glenn Tong
Invictus BioPharma Ltd.
Tel: +61 (0) 412 193 350

Andrew Geddes
CityPR
Tel: +61 (0) 2 9267 4511

About Invictus BioPharma Ltd.

Invictus BioPharma Ltd. is an Australian public unlisted biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. Invictus BioPharma owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines. For more information see: www.invictusbiopharma.com

About Professor Ed Gane, MBCHB, MD, FRACP, MNZM, FRSNZ



Dr. Gane is Professor of Medicine at the University of Auckland, New Zealand, Hepatologist and Deputy Director of the New Zealand Liver Unit at Auckland City Hospital. Dr. Gane trained in hepatology at the Institute of Liver Studies, King's College School of Medicine, London, where he completed his MD on the pathogenesis of hepatitis C-related liver injury. In 1998, Dr. Gane was appointed as Chief Physician for the first New Zealand Liver Unit at Auckland City Hospital, which provides a national transplant and HCC programme and regional hepatitis services. Dr Gane chairs the Ministry of Health HepC Implementation committee. Dr. Gane is an investigator for many international clinical trials with particular interest in early phase development of therapies for non-alcoholic fatty liver disease and new direct acting antiviral therapies against chronic hepatitis C and hepatitis B. He has published more than 300 papers in peer-reviewed journals including The Lancet and The New England Journal of Medicine. Dr Gane is a member of APASL and AASLD and is a Fellow of the Royal Society of New Zealand.